The global Myasthenia Gravis Treatment market size is predicted to grow from US$ 1971 million in 2025 to US$ 2915 million in 2031; it is expected to grow at a CAGR of 6.7% from 2025 to 2031.

Drug therapy for MG includes: (1) acetylcholinesterase inhibitors, (2) immunosuppressants, (3) immunomodulators. Introduce and gradually increase options based on international guidelines and the clinical and immunological characteristics of patients. Surgical treatments include (1) thymectomy, (2) median sternotomy and video-assisted thoracoscopic surgery, etc.

The major factors driving the market growth are increasing prevalence of myasthenia gravis, awareness for early diagnosis of myasthenia gravis, and adoption of new treatment options for myasthenia gravis. Rising prevalence of myasthenia gravis globally is one of the major drivers for the growth of the myasthenia gravis treatment market. For example, according to the Myasthenia Gravis Foundation of America, about 20 out of every 100,000 people in the United States have myasthenia gravis, and the disease is more common in women than men. Furthermore, the incidence of myasthenia gravis is increasing worldwide.

Infinity Market Research newest research report, the ?Myasthenia Gravis Treatment Industry Forecast? looks at past sales and reviews total world Myasthenia Gravis Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Myasthenia Gravis Treatment sales for 2025 through 2031. With Myasthenia Gravis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Myasthenia Gravis Treatment industry.

This Insight Report provides a comprehensive analysis of the global Myasthenia Gravis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Myasthenia Gravis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Myasthenia Gravis Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Myasthenia Gravis Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Myasthenia Gravis Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Myasthenia Gravis Treatment market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Monoclonal Antibodies
    Intravenous Immunoglobulin
    Other

Segmentation by Application:

    Hospital
    Specialist Clinic
    Other

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Amneal Pharmaceuticals, Inc.
    Astellas Pharma, Inc.
    Avadel Pharmaceuticals PLC
    Bausch Health Companies Inc.
    CSL Behring
    CuraVac, Inc.
    Argenx SE
    GlaxoSmithKline plc
    Immunovant, Inc.
    Mitsubishi Tanabe Pharma Corp.
    Novartis AG
    Takeda Pharmaceutical Co., Ltd.
    UCB Pharma
    AstraZeneca
    F. Hoffmann-La Roche Ltd

Key Questions Addressed in this Report

What is the 10-year outlook for the global Myasthenia Gravis Treatment market?
What factors are driving Myasthenia Gravis Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Myasthenia Gravis Treatment market opportunities vary by end market size?
How does Myasthenia Gravis Treatment break out by Type, by Application?